About Splendid Lab
Splendid Lab is a company based in Pune (India) founded in 2013 by Abhay Gandhi. Splendid Lab has raised $172.5 thousand across 2 funding rounds. Splendid Lab offers products and services including Pharmaceutical Impurities, Custom Synthesis, and Drug Intermediates. Splendid Lab operates in a competitive market with competitors including AFYREN, Clearbridge Health, Phylos Bioscience, Omass and Spore Biotechnologies, among others.
- Headquarter Pune, India
- Founders Abhay Gandhi
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Cro Splendid Lab Private Limited
- Date of Incorporation 22 Mar, 2016
- Jurisdiction Pune, Maharashtra, India
-
Annual Revenue
$190.21 K (USD)-30.17as on Mar 31, 2022
-
Net Profit
$12 K (USD)-25.82as on Mar 31, 2022
-
EBITDA
$68.67 K (USD)-31.89as on Mar 31, 2022
-
Total Equity Funding
$172.5 K (USD)
in 2 rounds
-
Latest Funding Round
$70 K (USD), Seed
Aug 04, 2014
-
Investors
Not available
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Splendid Lab
Splendid Lab offers a comprehensive portfolio of products and services, including Pharmaceutical Impurities, Custom Synthesis, and Drug Intermediates.
Supplies working references and standards for pharmaceutical research.
Provides tailored organic synthesis for drug development needs.
Offers intermediates for pharmaceutical and biotech applications.
People of Splendid Lab
Unlock access to complete
Unlock access to complete
Funding Insights of Splendid Lab
Splendid Lab has successfully raised a total of $172.5K across 2 strategic funding rounds. The most recent funding activity was a Seed round of $70 thousand completed in August 2014. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investments & Acquisitions by Splendid Lab
Investment portfolio details for Splendid Lab
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Splendid Lab
Detailed financials for Splendid Lab
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Splendid Lab Comparisons
Peer comparison for Splendid Lab
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Splendid Lab
Splendid Lab operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as AFYREN, Clearbridge Health, Phylos Bioscience, Omass and Spore Biotechnologies, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Analytical services are provided for microbiology, chemistry, and bioprocesses sectors.
|
|
| Locked | Locked | Locked |
Precision medicine services including urine and tissue testing are provided.
|
|
| Locked | Locked | Locked |
Developer of cannabis breeding tools for agriculture & other health purposes
|
|
| Locked | Locked | Locked |
Native mass spectrometry services for protein characterization are provided.
|
|
| Locked | Locked | Locked |
Microbial detection technology is developed for life science industries.
|
|
| Locked | Locked | Locked |
Service provider in analytical testing
|
Detailed competitors of Splendid Lab
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Splendid Lab
Complete news archive for Splendid Lab
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Splendid Lab
Splendid Lab was founded in 2013.
Splendid Lab is headquartered in Pune, India. It is registered at Pune, Maharashtra, India.
Splendid Lab is a funded company, having raised a total of $172.5K across 2 funding rounds to date.
Annual revenue of Splendid Lab is $190.21K as on Mar 31, 2022.
Splendid Lab was established in 2013 in Pune, India, as a provider of integrated services within the pharmaceutical and biotechnology sectors. Custom synthesis on a small scale, analytical services, and outsourcing are offered, including labeled APIs and metabolites. Customized and specialty packaging services are also provided. Clients encompass global pharmaceutical firms, biotechnology companies, specialty fine chemicals producers, clinical and bio-analytical CROs, universities, and research institutions.
Splendid Lab's top competitors include AFYREN, Perfectus Biomed and Spore Biotechnologies.
Splendid Lab offers Pharmaceutical Impurities, Custom Synthesis, and Drug Intermediates.